JPMorgan cuts target for Legend Biotech stock to USD 33

Published on 10/20/2026 at 19:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 387.50 million, up 51.90 percent year over year. Legend Biotech stock costs EUR 16.90 on October 20, 2026.

Analyst target reset

On October 9, 2026, JPMorgan lowered its Legend Biotech target from USD 35.00 to USD 33.00.
For the second quarter of 2026, revenue reached USD 387.50 million, up 51.90 percent year over year.
Legend Biotech stock costs EUR 16.90 at Lang & Schwarz on October 20, 2026 at 6:58 p.m. CEST.

LEGN, US52490G1022, Illustration mit AI erstellt.

Legend Biotech stock (ISIN US52490G1022) is priced at EUR 16.90 at Lang & Schwarz on October 20, 2026 at 6:58 p.m. CEST. On October 9, 2026, MarketBeat reported that JPMorgan lowered its target for Legend Biotech from USD 35.00 to USD 33.00 while maintaining a neutral rating. Nasdaq shares stood at USD 18.97 at 1:02 p.m. EDT on October 20, putting the stock 42.52 percent below the USD 33.00 target.

Second-quarter revenue reached USD 387.50 million

Legend Biotech reported USD 387.50 million in revenue for the second quarter of 2026, compared with USD 255.10 million in the second quarter of 2025. The increase was 51.90 percent year over year, and adjusted earnings per share reached USD 0.09 against a USD 0.07 consensus estimate, according to MarketBeat. The company develops cell therapies for cancer, led by CARVYKTI in multiple myeloma, according to Legend Biotech.

What does the USD 33 target imply?

The target is 42.52 percent above the Nasdaq price of USD 18.97 on October 20, 2026. That calculation places the latest analyst objective well above the current quote, while JPMorgan's neutral rating provides a counterweight to the target itself.

Stock stays near its yearly low

Legend Biotech's Nasdaq price of USD 18.97 on October 20, 2026 stood between a 52-week low of USD 16.24 and a 52-week high of USD 37.50. The USD 3.51 billion market capitalization and negative price-to-earnings ratio of 37.21 were also listed for October 20, 2026. Trading volume reached 468,646 shares at 1:02 p.m. EDT, giving investors a current market-size and liquidity reference.

Revenue growth meets a valuation test

The second-quarter revenue comparison is the central operating measure: USD 387.50 million versus USD 255.10 million a year earlier. Net income attributable to common shareholders was USD 33.20 million in the second quarter of 2026, compared with a USD 54.30 million loss in the first quarter of 2026. The next dated corporate event listed by the company was its September 24, 2026 annual meeting, while the second-quarter results were reported on August 11, 2026.

Price and target in one view

For investors, the key contrast is between the current Nasdaq quote of USD 18.97 and JPMorgan's USD 33.00 target, alongside revenue growth of 51.90 percent year over year. The stock's 52-week low of USD 16.24 leaves a measurable distance below the current quote, while the high of USD 37.50 remains substantially higher.

After-hours price perspective

The euro quotation was EUR 16.90 at Lang & Schwarz on October 20, 2026 at 6:58 p.m. CEST, during after-hours trading. The Nasdaq quote was USD 18.97 at 1:02 p.m. EDT on the same date.

The further course of trading is shown by the continuously updated real-time quote of Legend Biotech stock.